Regulatory Information
HSA regulatory responsibility and product classification details
Regulatory Responsibility
Product Classification
Formulation Information
TABLET
**Dosage and Administration** _For the Treatment of nausea induced by radiotherapy:_ Adults and children over 12 Years: One tablet every 6 to 8 hours, as required with a little water (up to a maximum of 3 tablets in 24 hours) Use in the Elderly: There have been no specific studies of cyclizine in the elderly. Experience has indicated that normal adult dosage is appropriate. _For the Prevention of Travel Sickness:_ Adults and children over 12 Years: One tablet every 6 to 8 hours (up to a maximum of 3 tablets in 24 hours), as required with a little water, first taken 1–2 hours before departure. The score line only serves to facilitate breaking for ease of swallowing and does not divide the tablet into equal half-doses. **This product should not be used for more than 48 hours at a time**
ORAL
Medical Information
**Indications** Nausicalm is indicated for the prevention and treatment of nausea and vomiting associated with motion sickness and radiotherapy.
**Contraindications** Nausicalm should not be given to individuals with known hypersensitivity to cyclizine or in individuals with severe heart failure.
R06AE03
cyclizine
Manufacturer Information
APEX PHARMA MARKETING PTE. LTD.
Sigma Laboratories Ltd.
Active Ingredients
Documents
Package Inserts
Nausicalm Tablet PI.pdf
Approved: June 14, 2017